Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
High-risk Prostate Cancer: early-phase trial registry
5 of 5 indexed High-risk Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count
High-risk Prostate Cancer: 5 US clinical trials tracked, 5 recruiting.
High-risk Prostate Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Thomas Hope, running 1 of these trials.
Enrollment posture brief
Registry condition high-risk-prostate-cancer
OPEN 5 | RECR 100% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
High-risk Prostate Cancer lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for High-risk Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
High-risk Prostate Cancer is recruiting above its size-band peers.
5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates High-risk Prostate Cancer research.
Thomas Hope accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most High-risk Prostate Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
High-risk Prostate Cancer research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Cellvax Therapeutics
NCT06636682
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
Thomas Hope
NCT07054346
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
NCT07027124
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
VA Office of Research and Development
NCT05593497
A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer
Edwin Posadas, MD
NCT06888102
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on High-risk Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on High-risk Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this High-risk Prostate Cancer page
5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 High-risk Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Thomas Hope sponsors the most High-risk Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Thomas Hope's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This High-risk Prostate Cancer condition card totals 5 registered trials; most-linked intervention Single-photon emission computed tomography (SPECT)/Computerized tomography (CT); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.